Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.35 |
| ▸ | HTR2B | P41595 | 5/20 | 0.35 |
| ▸ | HTR2A | P28223 | 4/20 | 0.35 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226587 | 0.75 | — | — | |
| SCHEMBL16327896 | 0.73 | HTR6 (0.32) | PNMT | |
| SCHEMBL13424027 | 0.70 | HTR6 (0.31) | — | |
| SCHEMBL17645602 | 0.65 | HTR6 (0.43) | HTR2CHTR2BHTR2APNMT | |
| SCHEMBL24914846 | 0.63 | PARP1 (0.37) | HTR2CHTR2BHTR2A | |
| SCHEMBL18074762 | 0.60 | HTR2C (0.46) | HTR2CHTR2BHTR2A | |
| SCHEMBL22845436 | 0.58 | HTR2C (0.36) | HTR2CHTR2BHTR2A | |
| SCHEMBL16220577 | 0.56 | MEN1 (0.34) | — | |
| SCHEMBL504599 | 0.56 | PKN2 (0.41) | — | |
| SCHEMBL16220603 | 0.55 | PNMT (0.38) | PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691842-B2 | Tricyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH LLC (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100063023-A1 | Bicyclic and Tricyclic Substituted 6-Methylidene Carbapenems as Broad Spectrum Beta-Lactamase Inhibitors | WYETH (US) | 2010-03-11 | — | — | US | disclosed |
| EP-1499622-B1 | HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASE INHIBITORS | WYETH CORP (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080318921-A1 | Tricyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| EP-1909786-A2 | TRICYCLIC 6-ALKYLIDENE-PENEM ß-LACTAMASE INHIBITORS AND ß-LACTAM ANTIBIOTIC COMBINATION: A BROAD SPECTRUM ANTIBIOTIC | Wyeth a Corporation of the State of Delaware (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1885358-A2 | TRICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D ß-LACTAMASES INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7229983-B2 | 4-substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as β-lactamase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2007030166-A2 | TRICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D β-LACTAMASES INHIBITORS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007027323-A2 | TRICYCLIC 6-ALKYLIDENE-PENEM β-LACTAMASE INHIBITORS AND β-LACTAM ANTIBIOTIC COMBINATION: A BROAD SPECTRUM ANTIBIOTIC | WYETH (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070027130-A1 | Tricyclic 6-alkylidene-penem beta-lactamase inhibitors and beta-lactam antibiotic combination: a broad spectrum antibiotic | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20060276446-A1 | Tricyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060074064-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH (US) | 2006-04-06 | — | — | US | disclosed |
| US-7018997-B2 | Tricyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1499622-A1 | HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASE INHIBITORS | Wyeth (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040214812-A1 | 4-Substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2004-10-28 | — | — | US | disclosed |
| US-20040043978-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH | 2004-03-04 | — | — | US | disclosed |
| WO-2003093280-A1 | HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS ΒΕΤΑ-LACTAMASE INHIBITORS | WYETH (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027130-A1 | Tricyclic 6-alkylidene-penem beta-lactamase inhibitors and beta-lactam antibiotic combination: a broad spectrum antibiotic | MGAM, B2M, PEPD | HTR2C 2906/4885HTR2B 3175/4885HTR2A 2031/4885 |
| US-20060074064-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, MGAM, PREP | HTR2C 2665/4885HTR2B 2531/4885HTR2A 1899/4885 |
| US-20040214812-A1 | 4-Substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors | DDC, AADAC, ALDH7A1 | HTR2C 1571/4885HTR2B 2903/4885HTR2A 2658/4885 |
| US-20080318921-A1 | Tricyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | PGLS, MGAM, PREP | HTR2C 2665/4885HTR2B 2531/4885HTR2A 1899/4885 |
| US-20060276446-A1 | Tricyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | PEPD, PGLS, MGAM | HTR2C 2291/4885HTR2B 2340/4885HTR2A 1726/4885 |
| US-20100063023-A1 | Bicyclic and Tricyclic Substituted 6-Methylidene Carbapenems as Broad Spectrum Beta-Lactamase Inhibitors | MGAM, CYP2C18, BCAT2 | HTR2C 3694/4885HTR2B 4354/4885HTR2A 4062/4885 |
| US-20040043978-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, MGAM, PREP | HTR2C 2916/4885HTR2B 2805/4885HTR2A 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.